Loading...
XKRX
019170
Market cap493mUSD
Dec 05, Last price  
14,770.00KRW
1D
1.03%
1Q
17.97%
Jan 2017
148.24%
Name

Shinpoong Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:019170 chart
P/E
—
P/S
3.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.51%
Rev. gr., 5y
3.11%
Revenues
221.09b
+10.42%
165,922,224,000188,135,653,000217,255,761,000232,060,469,000229,693,072,190221,169,380,010215,962,840,330220,291,937,930195,950,486,360194,147,337,500184,998,400,350187,389,168,040189,721,696,060197,750,767,000189,237,234,930209,287,628,000200,228,582,500221,094,070,000
Net income
-15.39b
L-73.16%
8,843,130,00012,051,001,00021,052,454,00021,734,263,00024,866,240,00014,377,490,0005,437,651,0003,349,617,3601,476,216,010-18,591,699,490904,889,0002,803,780,0005,323,827,0005,002,804,500-11,526,010,680-35,308,829,000-57,325,386,770-15,387,261,000
CFO
-15.15b
L-39.01%
9,765,566,00023,570,779,0009,818,846,00011,357,006,00028,726,635,85030,792,490,39011,453,530,130-48,156,6909,890,504,09018,959,223,22010,148,039,89032,054,460,36019,350,539,80020,062,347,350-71,027,968,120-26,443,578,950-24,847,572,600-15,154,793,000
Dividend
Dec 29, 2020100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
URL
https://shinpoong.co.kr/
IPO date
Jan 20, 1990
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT